Oct 2026· Current Geriatrics Reports· Vol 15· 0 citations· 125 references
TL;DR
SGLT2i and GLP-1 are safe and effective in older patients and offer cardiovascular benefits in older patients with type 2 diabetes with potential benefits of replacing other anti-diabetes agents and reducing polypharmacy.
In two large real-world cohorts of patients with T2D and CKD, the tree-based scan statistic identified previously known adverse events, but no new safety signals associated with SGLT2 inhibitor use compared with GLP-1RA use.
J. Ortega-Montiel, Wajd Alkabbani, Georg Hahn et al.· American Journal of Kidney D...· 0 citations
AIMS
Heart failure (HF) remains prevalent following pacemaker implantation, with patients with type 2 diabetes mellitus (T2DM) representing a particularly vulnerable population. Whether use of contemporary glucose-lowering therapies is associated with subsequent clinical outcomes has not been well characterized. We inv...
Yuval Avidan, Matan Jonas, Dana Hadar et al.· Current problems in cardiolo...· 0 citations
A clinical pharmacological analysis of current data is presented, discussing the mechanisms of action, clinical efficacy, safety, and strategies for personalized use of SGLT2 inhibitors and GLP-1 RAs in preventing cardiovascular and neurodegenerative complications in patients with type 2 diabetes and metabolic disorder...
E. N. Saykina, A. O. Kenkishvili, M. Maksimov et al.· Terapevt (General Physician)· 0 citations
PURPOSE OF REVIEW
Obesity is an increasingly important health problem in older adults (≥65 years) and is associated with osteoarthritis, impaired mobility, reduced quality of life, cardiovascular disease, and other age-related comorbidities. This narrative review summarizes the current evidence regarding the benefits a...
M. Kaşkal, U. Alam, Gregory Y. H. Lip· Current opinion in clinical...· 0 citations
OBJECTIVE
Sodium-glucose cotransporter 2 inhibitors (SGLT2is) have demonstrated cardiorenal benefits in individuals with type 2 diabetes, but safety data in older adults remain limited. We evaluated the real-world safety of SGLT2is compared with dipeptidyl peptidase 4 inhibitors (DPP-4is) among individuals aged ≥75 yea...
Hanin Harbi, Michael Nesrallah, G. Carney et al.· Diabetes Care· 0 citations